Voyager Therapeutics, Inc.

Voyager Therapeutics is a biotechnology company focused on developing therapies for severe neurological conditions, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Friedreich's ataxia. The company develops intravenous gene therapies and antibody treatments utilizing its proprietary TRACER adeno-associated virus capsid discovery platform and NeuroShuttle delivery system, which facilitate transport across the blood-brain barrier. Its pipeline consists of wholly owned drug candidates, such as tau-directed programs for Alzheimer's disease, as well as partnered programs. Its customers and commercial partners include global pharmaceutical and biotechnology corporations such as Novartis, Neurocrine Biosciences, and Alexion, which license Voyager's capsids and collaborate on research, development, and potential commercialization.

The provided text does not state the location of the company's headquarters, its facility count, or its employee numbers. Geographically, the company's collaborative agreements and licensing frameworks encompass operations in the United States and key international markets, including the United Kingdom, France, Germany, Italy, Spain, and Japan, alongside worldwide development and commercialization rights.

Summary of the business section of Voyager Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 141 full-time employees in the United States, including 112 in research and development positions and 29 in general and administrative positions.”